Westborough, MA, United States of America

Susan E Lacy

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 8.1

ph-index = 4

Forward Citations = 84(Granted Patents)


Location History:

  • Shrewsbury, MA (US) (2010 - 2014)
  • Westborough, MA (US) (2016 - 2018)

Company Filing History:


Years Active: 2010-2018

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Unveiling the Innovation Journey of Susan E Lacy: Pioneering Solutions in NGF Antibodies

Introduction

Susan E Lacy, a prolific inventor based in Westborough, MA, is a trailblazer in the field of biotechnology with a remarkable portfolio of 6 patents to her credit. Known for her groundbreaking work in developing antibodies targeting nerve growth factor (NGF), Susan's contributions have significantly advanced the realm of therapeutic interventions for disorders where NGF activity plays a pivotal role.

Latest Patents

Susan’s latest patents "Caninized anti-NGF antibodies and their use" and "Anti-NGF antibodies and their use" underscore the forefront of her innovative pursuits. These patents encapsulate the development of NGF binding proteins, particularly chimeric, CDR grafted, and canonized antibodies, along with their manufacturing methodologies and diverse applications. These antibodies hold immense potential in detecting NGF and modulating its activity, offering promising avenues for alleviating NGF-related disorders in mammalian subjects.

Career Highlights

Throughout her career, Susan E Lacy has lent her expertise to esteemed companies such as Zoetis Belgium S.A and AbbVie Inc., where her visionary approach towards biotechnological research has left an indelible mark. Her commitment to translating scientific ingenuity into tangible products underscores her proficiency in bridging the gap between innovation and application.

Collaborations

In her quest for groundbreaking advancements, Susan has collaborated with accomplished peers in the industry, including Emma Fung and Meha Chhaya. These collaborations have not only enriched the collaborative landscape within biotechnology but have also fostered a culture of innovation that propels the industry forward.

Conclusion

In conclusion, Susan E Lacy stands as a beacon of innovation, spearheading transformative developments in the realm of NGF antibodies. Her relentless pursuit of excellence, coupled with her profound understanding of biotechnological intricacies, cements her legacy as a pioneering inventor at the forefront of biotechnological innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…